Bo Cheng

7.4k total citations · 1 hit paper
77 papers, 1.5k citations indexed

About

Bo Cheng is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Bo Cheng has authored 77 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pulmonary and Respiratory Medicine, 27 papers in Oncology and 21 papers in Molecular Biology. Recurrent topics in Bo Cheng's work include Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Diagnosis and Treatment (14 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Bo Cheng is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Diagnosis and Treatment (14 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Bo Cheng collaborates with scholars based in China, United States and Australia. Bo Cheng's co-authors include Jianxing He, Wenhua Liang, Caichen Li, Shan Xiong, Jianfu Li, Ran Zhong, Xiuyu Cai, Junliang Chen, Xiaokun Wu and Hengrui Liang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nano Letters.

In The Last Decade

Bo Cheng

70 papers receiving 1.5k citations

Hit Papers

The association between CD8+ tumor-infiltrating lymphocyt... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis
    2021 211 citations Feng Li, Caichen Li et al. profile →

Peers

Bo Cheng
Bo Yu China
Yijun Tian China
Jinxuan Hou China
Ibrahim O. Bello Saudi Arabia
Nan Sun China
Takashi Sato Japan
Akanksha Verma United States
Wenchao Gu China
Zhixian Liu China
Thomas Nelius United States
Bo Yu China
Bo Cheng
Citations per year, relative to Bo Cheng Bo Cheng (= 1×) peers Bo Yu

Countries citing papers authored by Bo Cheng

Since Specialization
Citations

This map shows the geographic impact of Bo Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Cheng more than expected).

Fields of papers citing papers by Bo Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bo Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Cheng. The network helps show where Bo Cheng may publish in the future.

Co-authorship network of co-authors of Bo Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Bo Cheng. A scholar is included among the top collaborators of Bo Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bo Cheng. Bo Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Peng, Liang, Jinsheng Tao, Bo Wang, et al.. (2024). Development of a genome atlas for discriminating benign, preinvasive, and invasive lung nodules. SHILAP Revista de lepidopterología. 5(8). e644–e644. 2 indexed citations
3.
4.
Li, Jianfu, Shan Xiong, Bo Cheng, et al.. (2024). Diameter thresholds for pure ground-glass pulmonary nodules at low-dose CT screening: Chinese experience. Thorax. 80(2). 76–85. 2 indexed citations
5.
Cao, Yu, et al.. (2024). The m6A regulators in prostate cancer: molecular basis and clinical perspective. Frontiers in Pharmacology. 15. 1448872–1448872. 1 indexed citations
6.
Liang, Wenhua, Yun Feng, Bo Cheng, Jinghong Li, & Jiaxi He. (2023). 1263MO The impact of PET-CT and brain MRI for metastasis detection among patients with T1-stage lung cancer: Findings from a large cohort study. Annals of Oncology. 34. S732–S732.
7.
Cheng, Bo, Yong Zhou, Li Tian, et al.. (2023). Vascular mimicry induced by m6A mediated IGFL2-AS1/AR axis contributes to pazopanib resistance in clear cell renal cell carcinoma. Cell Death Discovery. 9(1). 121–121. 13 indexed citations
8.
Cheng, Bo, Shuang Yu, Yu Cao, et al.. (2022). Cuproptosis-Related MiR-21-5p/FDX1 Axis in Clear Cell Renal Cell Carcinoma and Its Potential Impact on Tumor Microenvironment. Cells. 12(1). 173–173. 48 indexed citations
9.
Chen, Zhuxing, Liping Liu, Feng Zhu, et al.. (2022). Dynamic monitoring serum tumor markers to predict molecular features of EGFR‐mutated lung cancer during targeted therapy. Cancer Medicine. 11(16). 3115–3125. 5 indexed citations
10.
Li, Caichen, Huiting Wang, Yu Jiang, et al.. (2022). Advances in lung cancer screening and early detection. Cancer Biology and Medicine. 19(5). 591–608. 51 indexed citations
11.
Deng, Hongsheng, Hengrui Liang, Jiawei Chen, et al.. (2022). Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers. Translational Lung Cancer Research. 11(12). 2364–2381. 16 indexed citations
12.
Liang, Wenhua, J. Li, Shan Xiong, et al.. (2022). LBA48 Community-based mass screening with low-dose CT for lung cancer in Guangzhou. Annals of Oncology. 33. S1414–S1414. 2 indexed citations
13.
Cheng, Bo, Hongsheng Deng, Yi Zhao, et al.. (2021). Management for Residual Ground-Glass Opacity Lesions After Resection of Main Tumor in Multifocal Lung Cancer: A Case Report and Literature Review. Cancer Management and Research. Volume 13. 977–985. 10 indexed citations
14.
Chen, Zhuxing, Feng Zhu, Caichen Li, et al.. (2021). Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report. Annals of Translational Medicine. 9(5). 424–424. 3 indexed citations
15.
He, Qihua, Jun Liu, Xiuyu Cai, et al.. (2021). Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations. Translational Lung Cancer Research. 10(11). 4120–4129. 9 indexed citations
16.
Liang, Hengrui, Zhichao Liu, Jun Huang, et al.. (2021). Identifying optimal candidates for primary tumor resection among metastatic non-small cell lung cancer patients: a population-based predictive model. Translational Lung Cancer Research. 10(1). 279–291. 14 indexed citations
17.
Liang, H., L. Chang, Yan Zhao, et al.. (2020). Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients. SHILAP Revista de lepidopterología. 2 indexed citations
18.
Tang, Qingming, Bo Cheng, Mengru Xie, et al.. (2016). Circadian Clock Gene Bmal1 Inhibits Tumorigenesis and Increases Paclitaxel Sensitivity in Tongue Squamous Cell Carcinoma. Cancer Research. 77(2). 532–544. 108 indexed citations
19.
Zhang, Bin, Bo Cheng, Fengsheng Li, et al.. (2015). High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma. Tumor Biology. 36(12). 9411–9419. 29 indexed citations
20.
Cheng, Bo, et al.. (2012). [Characteristics of anatomical structures and clinical significance of lumbar Jiaji (EX-B 2) points].. PubMed. 32(2). 139–42. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bo Yu Breakdown of academic impact, for papers by Yijun Tian Breakdown of academic impact, for papers by Jinxuan Hou Breakdown of academic impact, for papers by Ibrahim O. Bello Breakdown of academic impact, for papers by Nan Sun Breakdown of academic impact, for papers by Takashi Sato Breakdown of academic impact, for papers by Akanksha Verma Breakdown of academic impact, for papers by Wenchao Gu Breakdown of academic impact, for papers by Zhixian Liu Breakdown of academic impact, for papers by Thomas Nelius
Rankless by CCL
2026